Click here for eligibility criteria and study specifics.

Prostate cancer is the most common cancer in men.  In the United States there will be roughly 230,000 new cases diagnosed this year and about 30,000 men will die of the disease.  Prostate cancer is almost always an adenocaricinoma (99%).  Improvements in screening and management of this disease have lowered the death rate for prostate cancer but patients with disease that is widely spread are seriously ill.  Prostate cancer is almost always (90%) found to be at local or regional stage and 5-year survival approaches 100% for these men.  For patients whose disease has spread to distant sites, about 1/3 will survive 5 years.  Since many patients with prostate cancer are old enough to have other significant health issues treatment options may vary significantly, including nothing more than observation or symptomatic therapy.  For younger men who might otherwise expect to live substantially longer if their prostate cancer is brought under control, more aggressive treatment options are given greater consideration.

Additional information about prostate cancer can be found at the American Cancer Society website.  Additional information about clinical trials for treatment of lung cancer can be found at the National Cancer Institute.